Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from GSK

GSK vaccine shows ‘exceptional’ efficacy against common lung infection RSV

The pharmaceutical giant’s vaccine was found to be 82.6 per cent effective in Phase III clinical trials

Evening Standard

Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13

Reuters

Benzinga

Pollen does more than make you sneeze. It can cause thunderstorm asthma, even if you're not asthmatic

Climate change has caused melting icebergs, flooding, and landslides. It can also bring about an increase in pollen levels, prolong the duration of pollen season, and cause more pollen-related health problems.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Eamonn Holmes shares details of 'ghastly' health scare

Television presenter calls for more awareness and understanding to fight the illness

Wales Online

Questions you should ask your GP if you're concerned about your periods and gynae problems

Research shows one in four people have felt not listened to in a gynae health appointment - checklist shows how you can prepare for GP appointments so it feels less daunting

Daily Mirror

Bloomberg

Benzinga

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The only party not getting heartburn over GSK demerger is the lawyers

The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

The Guardian - UK

Sensodyne maker Haleon sees 22% profit rise in first results since GSK demerger

Haleon demerged from its parent company in July

Evening Standard

5 “Strong Buy” Health Care Stocks to Buy This Week

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

StockNews.com

3 Health Care Stock Under $50 You Can Buy Today

The healthcare industry is anticipated to grow significantly in the coming years, thanks to strong demand amid rising chronic diseases, technological advancements, and rising healthcare spending. Therefore, we think fundamentally sound healthcare companies Pfizer (PFE), GSK Plc (GSK), and Teva Pharmaceutical (TEVA), which are currently trading under $50, could be…

StockNews.com

How should New Zealand manage COVID from now – limit all infections or focus on preventing severe disease?

As the New Zealand government reviews mask mandates and other pandemic measures this week, we argue it’s time to reconsider the overall COVID strategy.

The Conversation

Chemical engineer fired by pharma giant GlaxoSmithKline after racist, homophobic rant on plane

Man mentioned employer GlaxoSmithKline in rant, calling it ‘one of the best f***ing companies in the world’

The Independent UK

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms

Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac.

Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Reuters

Exclusive-Rotavirus childhood vaccine shortage hits four African countries

Supplies of a vaccine to prevent the deadly rotavirus infection in children have either run out in Kenya, Tanzania, Senegal and Cameroon or are close to doing so, officials close to the roll-out told Reuters, after disruptions at drugmaker GSK.

Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

5 Value Stocks to Buy Ahead of the Fall Season

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Investors Business Daily

Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review

The stock market rally made big moves amid a barrage of earnings and economic reports and another big Fed rate hike.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Investors Business Daily

GSK's Shingrix Snags A Record Quarter, But Covid Antibody Sales To Fall

Revenue from GSK's blockbuster shingles vaccine, Shingrix, more than doubled in the second quarter, but GSK stock fell early Wednesday.

Evening Standard

FTSE 100 Live: Fed rates rise, Lloyds and GSK lift 2022 guidance

The US Federal Reserve has increased benchmark borrowing costs by 0.75% for the second time in a row, in the latest sign of the stronger measures being taken by central banks to try and tame runaway inflation.

The Independent UK

‘Silent killer’ disease researchers to receive £4.4m drug trial funding

Experts will aim to develop new treatments for Chagas disease, which can kill victims without them knowing they were infected.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations